Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, was one of the agents used early on for its anti-inflammatory effects, and immunomodulation response in the cytokine release syndrome (CRS) provoked by the virus [3]. Also, remdesivir (RDV), a nucleotide analog prodrug that inhibits viral RNA polymerases, has demonstrated in vitro activity against SARS-CoV-2 [4,5]. This evidence concerns the gene IL6 and congenital rubella syndrome.